<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03891693</url>
  </required_header>
  <id_info>
    <org_study_id>2018/2557</org_study_id>
    <nct_id>NCT03891693</nct_id>
  </id_info>
  <brief_title>Biomimetic Stent and Drug Eluting Balloon to Treat Recurrent Cephalic Arch Stenosis</brief_title>
  <acronym>Arch-V</acronym>
  <official_title>Biomimetic (SUPERA) Stent and Drug Eluting Balloon (Passeo 18 Lux) to Treat Recurrent Cephalic Arch Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the use of a biomimetic stent (SUPERA®) and a drug eluting balloon (DEB -
      Passeo 18 Lux) for the treatment of recurrent and tight cephalic arch stenosis in patients
      with brachiocephalic fistulas. All participants will undergo angioplasty with stated devices,
      and be followed up with over 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, the treatment options are limited for recurrent and tight cephalic arch stenosis in
      patients with brachiocephalic fistulas - Angioplasty, with or without the placement of a
      stent, surgical bypass using the internal jugular vein or a cephalic/brachial venous
      anastomosis, or the creation of a new fistula may be a reasonable option. Angioplasty may be
      associated with technical failure and rupture of the arch vein in reported incidences of 24%
      and 6%, respectively. Percutaneous Transluminal Angioplasty (PTA) is associated with very low
      primary patency rates of 42% and 23% at 6 and 12 months, whilst bare stents are equally poor,
      with reported patency of 39% and 0% at those same time-point. The use of a biomimetic stent
      (SUPERA®) in the cephalic arch has not been studied to date, but may not only offer
      protection from rupture of the arch vein but may also create a material barrier to prevent
      the development of Neo-Intimal Hyperplasia (NIH). With the additional use of drug elution,
      this may impede NIH effect even more.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects will be treated with SUPERA® stents and Passeo-18-Lux</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic Success</measure>
    <time_frame>Immediately post-operation</time_frame>
    <description>&lt;30% regional stenosis within the stent and minimal lumen size should reach 5mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Fistula</measure>
    <time_frame>Post-operation 1 week, 2 months, 6 months and 12 months.</time_frame>
    <description>At the following time points, to monitor for any changes in whether fistula can be used successfully for dialysis without the need for re-intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Patency of Cephalic Arch</measure>
    <time_frame>1 year post-operation</time_frame>
    <description>Less than 50% stenosis observed on duplex ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Access Circuit Thrombosis</measure>
    <time_frame>1 year post-operation</time_frame>
    <description>Thrombosis of access circuit requiring further intervention such as thrombolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of re-interventions per year</measure>
    <time_frame>1 year post-operation</time_frame>
    <description>To note any re-interventions performed post-study procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access Circuit Restenosis / Stent Fractures</measure>
    <time_frame>1 year post-operation</time_frame>
    <description>To note any restenosis or stent fractures during study period that requires re-intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access Circuit Infection</measure>
    <time_frame>1 year post-operation</time_frame>
    <description>To note any infection at treated fistula during study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for bypass revision surgery</measure>
    <time_frame>1 year post-operation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Brachiocephalic Vein Stenosis</condition>
  <arm_group>
    <arm_group_label>Passeo-18 Lux and SUPERA® stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target lesion will be treated with Passeo-18 Lux Drug Eluting Balloon and SUPERA® stent during angioplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Passeo-18 Lux and SUPERA® stent</intervention_name>
    <description>Angioplasty of Arteriovenous Fistula (AVF) performed using Passeo-18 Lux and SUPERA® stent for patients with cephalic arch stenosis</description>
    <arm_group_label>Passeo-18 Lux and SUPERA® stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient's age is above 21 and below 90

          -  Informed consent obtained

          -  Chronic background treatment with daily ASA

          -  Patients with significant Cephalic Arch Vein Stenosis or recurrent stenosis within 6
             months of initial POBA diagnosed either clinically or with Duplex Ultrasound

          -  Post-angioplasty cephalic arch lumen size between 5mm - 7mm maximum diameter

        Exclusion Criteria:

          -  Patients with significant central vein stenosis (&gt;70%) or total occlusion at time of
             angiographic study

          -  Cephalic arch stenosis &lt;50% stenosis or diameter &gt;5mm

          -  Patients with previous cephalic arch stenting (Bare Metal Stents or stent graft)

          -  Concomitant fistula inflow problem (e.g. juxta-anastomotic) that cannot be corrected
             optimally during the intervention (&gt;30% residual stenosis or angiographic lumen &lt;3mm)

          -  Patients with minor or major cephalic arch rupture during POBA procedure and the
             rupture point cannot be adequately sealed off during the procedure requiring a covered
             stent or open conversion

          -  Cephalic arch lesion length &lt;10mm or greater than 10cm

          -  Patients with uncontrolled hypertension

          -  Patient &lt;21 or &gt; 90 years of age.

          -  Pregnant women or women of childbearing potential who are not following an effective
             method of contraception.

          -  Contraindication to aspirin or clopidogrel usage

          -  Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences o the study, or language barrier such that the subject is unable
             to give informed consent.

          -  Uncooperative attitude or potential for non-compliance with the requirements of the
             protocol making study participation impractical

          -  Patients who do NOT have impaired renal function

          -  Occluded or thrombosed fistula

          -  Patients presenting with central venous stenosis

          -  Final angioplasty treatment requires a stent or DEB &gt;7mm in diameter

          -  Multiple lesions in the access circuit that cannot be treated with one stent and DEB.

          -  Vascular access circuit placed in the lower extremities

          -  Bare metal stent or stent-graft placed previously

          -  Metastatic caner or terminal medical condition

          -  Blood coagulation disorder

          -  Limited life expectancy (&lt;6 months)

          -  Sepsis or active infection

          -  Recent arm thrombophlebitis

          -  Allergy or other known contraindication to iodinated media contrast, heparin or
             paclitaxel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tang Tjun Yip</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charyl Yap</last_name>
    <phone>6576 7986</phone>
    <email>charyl.yap.j.q@sgh.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charyl Yap</last_name>
      <phone>65767986</phone>
      <email>charyl.yap.j.q@sgh.com.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Scheinert D, Werner M, Scheinert S, Paetzold A, Banning-Eichenseer U, Piorkowski M, Ulrich M, Bausback Y, Bräunlich S, Schmidt A. Treatment of complex atherosclerotic popliteal artery disease with a new self-expanding interwoven nitinol stent: 12-month results of the Leipzig SUPERA popliteal artery stent registry. JACC Cardiovasc Interv. 2013 Jan;6(1):65-71. doi: 10.1016/j.jcin.2012.09.011.</citation>
    <PMID>23347863</PMID>
  </reference>
  <reference>
    <citation>Garcia L, Jaff MR, Metzger C, Sedillo G, Pershad A, Zidar F, Patlola R, Wilkins RG, Espinoza A, Iskander A, Khammar GS, Khatib Y, Beasley R, Makam S, Kovach R, Kamat S, Leon LR Jr, Eaves WB, Popma JJ, Mauri L, Donohoe D, Base CC, Rosenfield K; SUPERB Trial Investigators. Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial. Circ Cardiovasc Interv. 2015 May;8(5). pii: e000937. doi: 10.1161/CIRCINTERVENTIONS.113.000937. Erratum in: Circ Cardiovasc Interv. 2015 Jun;8(6). pii: e000014. doi: 10.1161/HCV.0000000000000014.</citation>
    <PMID>25969545</PMID>
  </reference>
  <reference>
    <citation>Bishu K, Armstrong EJ. Supera self-expanding stents for endovascular treatment of femoropopliteal disease: a review of the clinical evidence. Vasc Health Risk Manag. 2015 Jul 13;11:387-95. doi: 10.2147/VHRM.S70229. eCollection 2015. Review.</citation>
    <PMID>26203255</PMID>
  </reference>
  <reference>
    <citation>Micari A, Brodmann M, Keirse K, Peeters P, Tepe G, Frost M, Wang H, Zeller T; IN.PACT Global Study Investigators. Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study. JACC Cardiovasc Interv. 2018 May 28;11(10):945-953. doi: 10.1016/j.jcin.2018.02.019.</citation>
    <PMID>29798770</PMID>
  </reference>
  <reference>
    <citation>Zeller T, Beschorner U, Pilger E, Bosiers M, Deloose K, Peeters P, Scheinert D, Schulte KL, Rastan A, Brodmann M. Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv. 2015 Oct;8(12):1614-22. doi: 10.1016/j.jcin.2015.07.011.</citation>
    <PMID>26493253</PMID>
  </reference>
  <reference>
    <citation>Zhang D, Yang R, Wang S, Dong Z. Paclitaxel: new uses for an old drug. Drug Des Devel Ther. 2014 Feb 20;8:279-84. doi: 10.2147/DDDT.S56801. eCollection 2014. Review.</citation>
    <PMID>24591817</PMID>
  </reference>
  <reference>
    <citation>Cho SB, Choi HC, Bae E, Park TJ, Baek HJ, Park SE, Ryu KH, Moon JI, Choi BH, Bae K, Jeon KN. Angioplasty and stenting for the proximal anastomotic stenosis of a brachio-axillary bypass graft using a helical interwoven nitinol stent: A case report. Medicine (Baltimore). 2017 Dec;96(50):e9073. doi: 10.1097/MD.0000000000009073.</citation>
    <PMID>29390303</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stenosis</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Vascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

